Ashok Seth 2012-08-10
Emerging Bioabsorbable Stent and Balloon Platforms: Are the days of metallic drug-eluting stents numbered?
Juan F. Granada 2012-08-09
2nd-generation drug-eluting stents, results for “real” patients at two years
Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press. In recent years there have been new drug-eluting...
Malapposition in drug-eluting stents. Much more common and much less serious than we thought
Original title: Incidences, Predictors, and Clinical Outcomes of Acute and Late Stent Malapposition Detected by Optical Coherence Tomography After Drug-Eluting Stent Implantation Reference: Im E. et al. CircCardiovascInterv. 2014 Jan 14. [Epubahead of print] This paper analyzed the imaging of 351 patients by optical coherence tomography (OCT) who received drug-eluting stents over 356 lesions between 2009 and...
Primary angioplasty with 2nd generation drug-eluting stents
Original title: Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: Network meta-analysis of primary percutaneous coronary intervention trials in ST-segment–elevation myocardial infarction. Reference: Circ Cardiovasc Interv. 2013; Epub ahead of print. To compare the safety and efficacy of 2nd generation drug-eluting stents (DES) versus bare metal stents (BMS) in the context of primary angioplasty was conducted...
Similar results of drug-eluting stents with biodegradable polymer versus permanent
Original title: Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentA Randomized, Controlled, Noninferiority Trial.NEXT trial. Reference: Masahiro Natsuaki et al. J Am CollCardiol 2013;62:181–90. Drug-eluting stents with biodegradable polymer were designed to counteract the long-term adverse effects on the vascular wall of permanent polymer. This prospective, multicenter, randomized, non-inferiority design study, compared the biolimus eluting stent with...
2nd generation drug-eluting stents intended for left main coronary artery
Original title: Zotarolimus- versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. ISAR-LEFT MAIN 2 Study. Reference: Julinda Mehilli et al. J Am Coll Cardiol, article in press. Improvements in 2nd generation drug-eluting stents led to increased efficiency and safety , however there is little information on these new platforms to treat left main coronary artery ....
Safety and superior effectiveness over two years in femoropopliteal region with drug-eluting stents
Original title: Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: two-year follow-up from the Zilver PTX randomized and single-arm clinical studies. Reference: Michael D. Dake et al. J Am Coll Cardiol 2013. Article in press. Studies with long-term monitoring showed mainly the limited permeability of balloon angioplasty, especially over challenging injuries such as total occlusions or...
Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents
The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,...
Arterial Patency in Femoropopliteal Disease with Drug-Eluting Balloons
Follow-up of drug-coated balloon angioplasty in femoropopliteal disease in a real-world population. Using drug-releasing devices has decreased the rate of restenosis in obstructive femoropopliteal lesions compared with conventional balloons or conventional stents (bare-nitinol stent, BNS). Both in the placement of BNS and of drug-eluting stents (DES) there is a mechanical risk of stent fracture or...